Coya Therapeutics, Inc. (COYA) Price & Analysis

Compare

83 Followers

COYA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.65 - $10.24

Previous CloseN/A

Volume16.99K

Average Volume (3M)76.86K

Market Cap

N/A

Enterprise Value$66.41M

Total Cash (Recent Filing)$29.76B

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.29

Next Earnings

Nov 05, 2025

EPS Estimate

-0.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.36

Shares Outstanding16,725,080

10 Day Avg. Volume104,610

30 Day Avg. Volume76,863

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/Revenue156.83

Enterprise Value/Gross Profit164.82

Enterprise Value/Ebitda-0.01

Forecast

1Y Price Target

$16.60

Price Target Upside147.39% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Financial MilestonesThe FDA's acceptance of the IND triggers a $4.2M milestone payment to Coya from its strategic partner, Dr. Reddy's Laboratories.

Regulatory ProgressCoya Therapeutics announced that the FDA had accepted its Investigational New Drug (IND) application for COYA 302, allowing it to enter the next stage of clinical development.

Bears Say

Clinical RisksRisks include clinical setbacks involving COYA 302 in ALS and/or AD, and failure to secure U.S. regulatory approval.

Regulatory RisksRisks include inability to advance into pivotal development and poorer-than-anticipated commercial uptake.

Coya Therapeutics, Inc. News

Coya receives $4.2M milestone payment after FDA approval of IND for Coya 302

Coya Therapeutics (COYA) announces that the FDA has accepted its Investigational New Drug, or IND, application for COYA...

5d ago

COYA

Coya Therapeutics files $75M mixed securities shelf

08:36 EDT Coya Therapeutics (COYA) files $75M mixed securities shelf Published first on TheFly – the ultimate source...

18d ago

COYA

Coya Therapeutics reports Q2 EPS (36c), consensus (43c)

Reports Q2 revenue $200K, consensus $668.57K. As of June 30, 2025, Coya had cash and cash equivalents of...

18d ago

COYA

Positive Outlook for Coya Therapeutics Amid Promising Developments and Financial Stability

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Coya Therapeutics, Inc. and keeping the price...

5d ago

COYA

Coya Therapeutics Reports Increased Losses Amid Development Focus

Coya Therapeutics, Inc. ( ($COYA) ) has released its Q2 earnings. Here is a breakdown of the information...

17d ago

COYA

Coya Therapeutics Highlights Q2 2025 Financial Results

Coya Therapeutics, Inc. ( ($COYA) ) has provided an update. Coya Therapeutics reported its financial results for the...

18d ago

COYA

Is COYA a Buy, Before Earnings?

Coya Therapeutics, Inc. (COYA) is scheduled to report 2nd quarter earnings on 08/12/2025. Regarding Q2 estimates, Wall Street...

20d ago

COYA

Coya Therapeutics publishes new research study on progression of Parkinson’s

Coya Therapeutics (COYA) announced the publication of a new research study, partially funded by Coya. The study, led...

1M ago

COYA

Sixteen new option listings on July 23rd

New option listings for July 23rd include ABVC Biopharma Inc (ABVC), Astex Pharmaceuticals Inc (ASTX), Bitmine Immersion Technologies...

1M ago

RAL

SMU

Coya Therapeutics initiated with a Buy at Lake Street

Lake Street initiated coverage of Coya Therapeutics (COYA) with a Buy rating and $16 price target The firm...

2M ago

COYA

Positive Outlook for Coya Therapeutics, Inc. Driven by IND Resubmission and Promising Trial Results

Coya Therapeutics, Inc. (COYA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst...

2M ago

COYA

Coya Therapeutics Holds Annual Stockholders Meeting

Coya Therapeutics, Inc. ( ($COYA) ) just unveiled an update. On June 26, 2025, Coya Therapeutics, Inc. held...

2M ago

COYA

Coya Therapeutics: Strengthened Patent Estate and Upcoming Catalysts Support Buy Rating

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on COYA stock, giving a Buy rating today....

3M ago

COYA

Coya Therapeutics initiated with a Buy at Lucid Capital

Lucid Capital analyst Elemer Piros initiated coverage of Coya Therapeutics (COYA) with a Buy rating and $20 price...

3M ago

COYA

COYA FAQ

What was Coya Therapeutics, Inc.’s price range in the past 12 months?

Coya Therapeutics, Inc. lowest stock price was $4.65 and its highest was $10.24 in the past 12 months.

What is Coya Therapeutics, Inc.’s market cap?

Currently, no data Available

When is Coya Therapeutics, Inc.’s upcoming earnings report date?

Coya Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 67 days.

How were Coya Therapeutics, Inc.’s earnings last quarter?

Coya Therapeutics, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.419 by $0.059.

Is Coya Therapeutics, Inc. overvalued?

According to Wall Street analysts Coya Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Coya Therapeutics, Inc. pay dividends?

Coya Therapeutics, Inc. does not currently pay dividends.

What is Coya Therapeutics, Inc.’s EPS estimate?

Coya Therapeutics, Inc.’s EPS estimate is -0.24.

How many shares outstanding does Coya Therapeutics, Inc. have?

Coya Therapeutics, Inc. has 16,725,080 shares outstanding.

What happened to Coya Therapeutics, Inc.’s price movement after its last earnings report?

Coya Therapeutics, Inc. reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.419. Following the earnings report the stock price went down -0.325%.

Which hedge fund is a major shareholder of Coya Therapeutics, Inc.?

Currently, no hedge funds are holding shares in COYA

Company Description

Coya Therapeutics, Inc.

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Coya Therapeutics, Inc. (COYA) Earnings & Revenues

Historic Earnings Reports

COYA Stock 12 Month Forecast

Average Price Target

$16.60

▲(147.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","21":"$21","8.25":"$8.25","12.5":"$12.5","16.75":"$16.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8.25,12.5,16.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.09,7.16,8.23,9.3,10.370000000000001,11.440000000000001,12.51,13.58,14.65,15.72,16.79,17.86,18.93,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.09,6.898461538461539,7.706923076923077,8.515384615384615,9.323846153846155,10.132307692307693,10.94076923076923,11.74923076923077,12.557692307692308,13.366153846153846,14.174615384615386,14.983076923076924,15.791538461538462,{"y":16.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.09,6.6984615384615385,7.306923076923077,7.915384615384616,8.523846153846154,9.132307692307693,9.740769230769232,10.349230769230768,10.957692307692309,11.566153846153846,12.174615384615386,12.783076923076923,13.391538461538461,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.62,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.03,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.68,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.04,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.73,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.31,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.28,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.55,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.09,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >